ADVA
20.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has upgraded its complete portfolio of Oscilloquartz PTP grandmaster clocks, enabling power utilities to smoothly transition to packet network synchronization. The enhanced technology will empower electricity providers to evolve their infrastructure into smart grids based on Precision Time Protocol (PTP) power profiles, while at the same time supporting all legacy timing signals. Updates to ADVA’s Oscilloquartz pluggable solution, its compact small cell device, its mid-size PTP grandmasters and its fully redundant core timing technology ensure ultra-precise timing throughout the utility network. What’s more, the technology removes the risk of relying purely on satellite-based time sources through continuous monitoring, jamming and spoofing detection and AI-assisted analytics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005048/en/
“Our upgraded technology makes it simple to modernize utility infrastructure. Now, power network operators can achieve the accurate and stable synchronization needed to develop smart grid power networks built on packet-based solutions, while also maintaining legacy timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our technology provides a clear and cost-efficient path to robust and future-proof utility network synchronization. Its PTP timing delivery complements and replaces legacy protocols, enabling the accurate and resilient timing needed for emerging intelligent applications. Along with our multi-constellation GNSS receivers, PTP backup is also essential for protecting critical power networks. This ensures efficient operations and the best protection from malicious attacks.”
ADVA’s entire range of Oscilloquartz grandmaster clocks has been upgraded to meet the latest PTP profiles for time, frequency and phase synchronization in power utility networks. This includes the OSA 5401 small form-factor pluggable, the OSA 5405 for indoor and outdoor substation deployments, the OSA 5420 Series, and the highly scalable OSA 5430 and 5440 with 10Gbit/s interfaces and fully redundant hardware. The technologies enable an easy migration to an Ethernet-based timing network with support for PTP, Network Time Protocol (NTP) and SyncE, as well as IRIG-B, PPS and BITS legacy interfaces. PTP-based backup combined with multi-band GNSS receivers and advanced monitoring capabilities ensure that the upgraded solutions provide highly reliable delivery of precise timing information even during long GNSS outages. And, to create an ePRTC solution, ADVA’s Oscilloquartz cesium clocks can also be combined with the OSA 5420, 5430 or 5440. This delivers extended holdover of up to 70 nanoseconds for 14 days, even when GNSS signals are unavailable.
”By optimizing our synchronization technology, we’re enabling power utilities to achieve the stringent levels of precision necessary for synchronization from the substation to the core of the smart grid network. Our comprehensive portfolio empowers utilities to complement and then replace their legacy timing protocols with PTP. What’s more, our continually evolving software supports the broadest range of interfaces and profiles, ensuring a solution ready to grow with future needs,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. ”IRIG-B and NTP have served the utility industry well. But the future is all about PTP power profiles delivering new levels of precision and reliability to substations with or without GNSS. This upgrade ensures operators can rely on extremely accurate frequency, phase and time services without the threat of outages caused by jamming and spoofing.”
Watch this video for more information: https://youtu.be/iHA_TI32T6A .
Further details are also provided in these slides: https://adva.li/power-utilities-slides .
A supporting solution sheet is available here: https://adva.li/smart-grids-solution-sheet .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005048/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom